Net profit nearly doubling, up 95% year-on-year to RMB 371 million, is the kind of number that reframes a company’s story. Sunshine Guojian’s 2026 interim results show a business moving faster than most China-based antibody developers at comparable pipeline stages, and the underlying driver is not one product but a constellation of late-stage assets converging on approval or readout at the same time. Total operating revenue hit RMB 866 million in the first half, a 34.84% increase, while R&D spend rose in lockstep at 32.41% to RMB 245 million. That ratio matters: the company is not extracting margin by cutting science.
Two NMPA approvals define the half. Amdokitug (Yisaituo, R&D code 608), an anti-IL-17A monoclonal antibody, cleared for moderate-to-severe plaque psoriasis in February after a 458-patient Phase 3 trial demonstrated strong PASI response rates. Phase 3 enrollment for ankylosing spondylitis is now complete, and the non-radiographic axial spondyloarthritis study has its first subject enrolled, building the indication stack that sustains a biologic franchise long-term. The second approval, Anflekitug (Yisaina, 613), is an anti-IL-1β monoclonal antibody for acute flares of gouty arthritis in patients who have failed or cannot tolerate NSAIDs, colchicine, or repeated corticosteroid use. The gout IL-1β class in China is no longer empty: firsekibart received NMPA approval for the same acute gout indication in July 2025, meaning Anflekitug enters a defined competitive lane rather than a blank one.
The Pfizer collaboration on SSGJ-707 (PF-08634404) underpins the financial story beyond domestic sales. Pfizer’s ex-China exclusive license, announced in May 2025, included a $1.25 billion upfront payment to 3SBio and up to $4.8 billion in additional milestone payments, with Sunshine Guojian positioned as a key participant in that program. Nine global multicenter trials across non-small cell lung cancersmall cell lung cancer and colorectal cancer are now active, and milestone receipts will accumulate as those studies hit their triggers. The anti-IL-4Rα candidate (611) for atopic dermatitis, with its NDA accepted for review in February, adds a third commercial-stage asset in a category where domestic competition including stapokibart from Keymed Biosciences is already in market.
The single marker worth watching is the NMPA review timeline for the 611 atopic dermatitis NDA. Approval in the next 12 months would give Sunshine Guojian three commercial biologics simultaneously, a rare position for a company this size, and would test whether its commercial infrastructure can scale across immunology franchises at once. That execution question, not the pipeline science, is now the central risk.
Source link: https://www.prnewswire.com/news-releases/sunshine-guojian-releases-2026-interim-report-302856882.html
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
